Abbott's new Kaltera tablet gets CHMP's OK
USA-based health care major Abbott Laboratories says that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use has recommended approval of a new tablet formulation of its protease inhibitor Kaletra (lopinavir/ritonavir).
The drug, which is approved by the EMEA for the treatment of HIV, is currently available in a capsule formulation which comprises 133.3mg of lopinavir and 33.3mg of ritonavir. The CHMP's positive opinion relates to a new tablet formulation of the compound, developed using the firm's Meltrex melt-extrusion technology, which combines 200mg of lopinavir and 50mg of ritonavir. The company says that the new formulation reduces the number of tablets required, does not need refrigeration and can be taken with or without food.
The CHMP's decision is based on data from a pharmacokinetic assessment of the product that Abbott submitted to the EMEA last year (Marketletter May 9, 2005), and follows the US Food and Drug Administration approval that it received late in 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze